Colorectal Cancer | Specialty

Considerations When Selecting an EGFR Inhibitor in mCRC

February 26th 2014

First- and Later-line Use of Panitumumab in mCRC

February 26th 2014

Treatment of Unresectable RAS Wild-type Metastatic CRC

February 26th 2014

Upfront Bevacizumab and Cetuximab Compared in mCRC

February 26th 2014

Clinical Development of Cetuximab in mCRC

February 26th 2014

Optimizing Treatment With EGFR Inhibitors in CRC

February 26th 2014

Introduction: Expanded RAS Testing in Colorectal Cancer

February 26th 2014

Minimally Invasive Techniques Make Strides in Liver Surgery

February 25th 2014

During the past 15 years, minimally invasive general surgery has rapidly expanded to include laparoscopic and robotic techniques for cholecystectomy, colectomy, gastric weight loss, and other procedures

Dr. Fakih on Angiogenesis Versus EGFR Inhibitors in CRC

February 25th 2014

Marwan G. Fakih, MD, professor, director, Gastrointestinal Medical Oncology, City of Hope, discusses anti-angiogenesis versus anti-EGFR therapy in patients who have RAS wild-type colorectal cancer.

Hopes Revived for Targeting the "Undruggable" RAS Family

February 11th 2014

The members of the RAS oncogene family are central cogs in many different cell-signaling pathways, coordinate a variety of important cellular processes, and are highly mutated in a number of different cancers, including several with extremely poor prognosis.

ALK and ROS1 Lung Cancer Oncogenes May Also Drive Colorectal Cancer

February 7th 2014

Gene rearrangements ALK and ROS1 that are known to drive subsets of lung cancer are also present in colorectal cancer according to a recent study in Molecular Cancer Research.

Dr. Peeters on KRAS/NRAS Mutations in mCRC

February 6th 2014

Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses an analysis of RAS mutations in the phase III study 20050181, which compared panitumumab plus FOLFIRI versus FOLFIRI for second-line treatment of mCRC

Robert McCormack Explains the CellSearch CTC Test

February 5th 2014

Robert McCormack, PhD, head, Technology Innovation, Janssen Diagnostics, LLC, explains the circulating tumor cell test CellSearch.

Cytoreductive Surgery and HIPEC for Peritoneal Carcinomatosis

February 5th 2014

The management of patients with malignant peritoneal surface disease (PSD) commonly known as "carcinomatosis" continues to evolve.

Examining the Role of Vitamin D in Colorectal Cancer Survival

January 27th 2014

Epidemiologic and scientific research indicates that diet and other lifestyle factors have a significant influence on the risk of developing colorectal cancer.

Dr. Bordonaro on First-Line Treatment Options for mCRC

January 24th 2014

Roberto Bordonaro, MD, discusses first-line treatment options for advanced colorectal cancer (CRC).

Dr. Fakih on RAS Mutations in Colon Cancer

January 22nd 2014

Marwan G. Fakih, MD, professor, director, Gastrointestinal Medical Oncology, City of Hope, discusses extended RAS mutations in colon cancer.

RAS Mutational Analyses in mCRC Trials Highlight Need to 'Think Beyond KRAS'

January 20th 2014

Studies presented at the 2014 GI Cancers Symposium emphasized the need for full RAS mutational analyses in the management of metastatic colorectal cancer prior to initiating treatment with anti-EGFR monoclonal antibodies.

Dr. John Marshall Provides Colorectal Cancer Updates

January 17th 2014

John L. Marshall, MD, from Georgetown University Hospital, on the recent advancements in colorectal cancer.

Neoadjuvant Capecitabine Considered a New Standard of Care in Rectal Cancer

January 14th 2014

Single-agent neoadjuvant capecitabine combined with radiation therapy demonstrated similar outcomes as previously established standards of care for patients with stage II or stage III rectal cancer.